Skip to main
IRON
IRON logo

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine Inc. is positioned favorably in the biopharmaceutical sector with a robust pipeline targeting hematologic diseases, highlighted by nearly universal patient-reported improvements in quality of life from the HELIOS OLE study, which bolsters confidence in bitopertin's effectiveness. The company’s strategic focus on addressing anemia in chronic conditions, as evidenced by the promising data on DISC-0974, suggests a significant market opportunity, particularly as competitors navigate tolerability challenges. Additionally, the rapid enrollment in key exploratory cohorts reflects strong clinical interest and provides further validation of the company’s therapeutic potential, reinforcing a positive outlook for future developments.

Bears say

Disc Medicine Inc faces challenges in accessing a patient population due to a significant number of individuals dropping out of the medical system, attributed to a lack of effective treatment options for their hematologic diseases. The company’s pipeline is hindered by complications such as high hepcidin levels, which restrict iron availability necessary for erythropoiesis, thereby impeding the effectiveness of potential therapies. Furthermore, conditions associated with their lead indication, such as erythropoietic protoporphyria (EPP), come with serious health risks including liver fibrosis and failure, potentially leading to concerns about market viability and treatment acceptance among patients.

IRON has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Strong Buy based on their latest research and market trends.

According to 9 analysts, IRON has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.